News & Updates
Filter by Specialty:
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
Use of famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, leading to rapid resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity, according to the results of a phase II trial.
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
25 Feb 2022
Baricitinib keeps radiographic progression levels low in rheumatoid arthritis
Treatment with oral baricitinib steadily inhibits radiographic progression of structural joint damage in most patients with rheumatoid arthritis (RA), while achieving clinical improvement in disease activity, through 5 years as compared with initial conventional synthetic disease-modifying antirheumatic drug (csDMARD) or placebo, results of a study have shown.
Baricitinib keeps radiographic progression levels low in rheumatoid arthritis
24 Feb 2022
Add-on trilaciclib boosts antitumour effects of chemo combinations for triple-negative breast cancer
Pretreatment with the cyclin-dependent kinase 4/6 inhibitor trilaciclib appears to enhance the antitumour efficacy of gemcitabine plus carboplatin, with significant survival gains for patients with metastatic triple-negative breast cancer (mTNBC), according to the results of a phase II trial.